Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries With Korean Firm
GOLDEN: PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D®) in Korea.
The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval (EUA) by India's national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income countries in Latin America and Asian New Southern Policy member countries. It is exclusively delivered by the PharmaJet Tropis® Needle-free Injection System.
Also Read:Zydus Pharma bags USFDA nod for Pimavanserin Capsules
Under the terms of this agreement, Zydus will transfer its manufacturing technology and provide technical assistance to Enzychem Lifesciences. The vaccine is administered intradermally using the PharmaJet needle-free system, which can be deployed more readily, especially in resource-poor populations where these are urgently needed.
Chris Cappello, President and CEO of PharmaJet, added, "This manufacturing agreement will enable people in lower-middle income countries access to a safe, well-tolerated and efficacious vaccine, delivered by a proven delivery system. Our systems have been successfully used to deliver millions of doses for polio immunization initiatives in Pakistan, Somalia, The Gambia, and numerous other countries. We are prepared for this commercialization initiative and have scaled our operations to meet the demand driven by COVID-19 vaccinations as we continue to fulfill our company mission of improving peoples' lives through our needle-free delivery technology."
